Ratings & Reviews

Zyprexa is an atypical antipsychotic that was approved for the treatment of the manifestations of psychotic disorders in 1996.  The FDA approved Zyprexa for use in the treatment of depressive episodes associated with bipolar disorder in 2003.  In 2004, the FDA approved Zyprexa for the long-term treatment of bipolar I disorder.  Zyprexa was also approved for the treatment of residual depression in 2009.  Zyprexa is marketed and manufactured by Eli Lilly and Company.

The use of Zyprexa may result in a number of side effects, including restlessness, dry mouth, dizziness, irritability, insomnia, constipation, weight gain, seizures, dental problems, hyperglycemia and hallucinations.  In addition, Zyprexa has been linked to more serious side effects, such as tardive dyskinesia, permanent brain damage and diabetes mellitus.

In 2003, the FDA ordered Eli Lilly to warn patients of the risk of hyperglycemia, diabetes, ketoacidosis, pancreatitis and other conditions resulting from the use of Zyprexa.  In 2005, the FDA ordered Eli Lilly to include a Black Box Warning in Zyprexa labeling regarding the risk of a higher death rate among elderly dementia patients taking the drug.  In 2009, Eli Lilly pled guilty to charges that it illegally marketed Zyprexa for the treatment of dementia.  While the FDA approved the use of Zyprexa for the treatment of schizophrenia and bipolar disorder, it did not approve Zyprexa for the treatment of dementia.  In 2004, the FDA notified health care providers of changes in Zyprexa labeling which discuss the increased risk of hyperglycemia and diabetes.